Jason Harris

Articles

Patients With Treatment-Naïve RCC Achieve Superior QoL With Nivolumab/Cabozantinib

January 29, 2022

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.